---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000161"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:55:04.177458+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application

## Summary
- Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.
- Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.
- CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.
- Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.
- XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs.

## SEC filing metadata
- accession: 0001867096-25-000161
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/0001867096-25-000161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/xers-20251201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000161
- JSON: https://secwatch.observer/filing/0001867096-25-000161.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.